Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Pemetrexed in EGFR Wild-Type/FISH-Positive Lung Adenocarcinoma
NCT01565538Phase 2Completed
- Start
- Dec 2008
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in lung adenocarcinoma (2 arms). Primary endpoint: Progression-Free Survival at 12 months. Started Dec 2008; status: completed.
02
Drugs
erlotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01565538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565538.